Alpine Immune ticks higher as HSR waiting period for Vertex Pharma deal expires
Seeking Alpha News (Fri, 10-May 12:44 PM ET)
RBC Capital Sticks to Its Hold Rating for Alpine Immune Sciences (ALPN)
TipRanks (Fri, 10-May 6:39 AM ET)
Alpine Immune Sciences GAAP EPS of -$0.28 beats by $0.12, revenue of $7.03M beats by $3.51M
Seeking Alpha News (Thu, 9-May 5:50 PM ET)
Alpine Immune Sciences Communicates Key Updates Regularly
TipRanks (Thu, 9-May 4:24 PM ET)
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
Business Wire (Thu, 9-May 4:00 PM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRC, HRT, ALPN, MCBC
PRNewswire (Mon, 29-Apr 10:38 PM ET)
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN
Globe Newswire (Sat, 27-Apr 8:47 AM ET)
Business Wire (Fri, 26-Apr 4:13 PM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIRC, ALPN, WIRE
PRNewswire (Tue, 23-Apr 12:05 PM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN
Globe Newswire (Mon, 22-Apr 11:12 AM ET)
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Alpine Immune Sciences trades on the NASDAQ stock market under the symbol ALPN.
As of May 14, 2024, ALPN stock price declined to $64.94 with 724,601 million shares trading.
ALPN has a beta of 2.55, meaning it tends to be more sensitive to market movements. ALPN has a correlation of 0.10 to the broad based SPY ETF.
ALPN has a market cap of $4.45 billion. This is considered a Mid Cap stock.
Last quarter Alpine Immune Sciences reported $7 million in Revenue and -$.28 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.13.
In the last 3 years, ALPN stock traded as high as $64.96 and as low as $4.82.
The top ETF exchange traded funds that ALPN belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.
ALPN has outperformed the market in the last year with a return of +694.9%, while the SPY ETF gained +28.2%. In the last 3 month period, ALPN beat the market returning +125.7%, while SPY returned +5.8%. However, in the most recent 2 weeks ALPN has underperformed the stock market by returning +0.4%, while SPY returned +2.1%.
ALPN support price is $63.51 and resistance is $66.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALPN stock will trade within this expected range on the day.